top of page
Pipeline AIM Biologicals AEZS-150 AEZS-130 (Macimorelin) Macimorelin Dx
Therapeutic Development Pipeline
Diagnostic Pipeline

Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories.
Specialty Biopharmaceutical Company
Data delayed 15 minutes unless otherwise indicated
bottom of page